|
Development Activities at Shionogi
USA
Shionogi USA currently supports the clinical development
of several compounds for the treatment of HIV/AIDS, neurological conditions,
and asthma.
| Compound |
Development Phase |
Method
of action |
Indication(s) |
| S-2367 |
Phase IIb |
NPY Y5 receptor antagonist |
Obesity |
| S-777469 |
Phase II |
Cannabinoid 2 receptor agonist |
Atopic Dermatitis |
| S-349572* |
Phase I |
Integrase Inhibitor |
HIV |
| S-265744/S-247303* |
Phase I (in preparation) |
Integrase inhibitor |
HIV |
| S-555739 |
Phase
I |
Prostoglandin D2 receptor antagonist
|
Allergic Rhinitis |
| S-888711 |
Phase I |
Thrombopoietin receptor agonist |
Thrombocytopenia |
| S-0139 |
Phase II |
Endothelin a receptor antagonist |
Stroke |
| S-0373 |
Pre-clinical |
Thyrotropin releasing hormone analogue |
Spino-cerebellar ataxia |
Compounds marked by * are being developed through Shionogi-GlaxoSmithKline
Pharmaceuticals, LLC, a joint venture that Shionogi USA supports.
In addition, Shionogi USA expects to further expand it’s portfolio
to include additional compounds originated by Shionogi Research Laboratories
in Japan.
To learn more about our R&D activities, click on the following headings:
HIV
Neurology
Other areas
|
